Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATO: glofitamab + pirtobrutinib in mantle cell lymphoma
2024-512922-27-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Nov 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of glofitamab and pirtobrutinib in mantle cell lymphoma (MCL) (2 cohorts), sponsored by LMU Klinikum. Primary endpoint: Progression-free survival status at 24 months. Planned start Nov 2025; status: authorised.
02
Drugs
glofitamabpirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-512922-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512922-27-00.